Illumina, Inc. (NASDAQ:ILMN) – Analysts at Leerink Swann issued their FY2019 earnings per share estimates for Illumina in a research report issued to clients and investors on Monday. Leerink Swann analyst P. Souda expects that the life sciences company will post earnings per share of $5.24 for the year. Leerink Swann currently has a “Outperform” rating and a $225.00 price objective on the stock.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/12/illumina-inc-expected-to-post-fy2019-earnings-of-5-24-per-share-ilmn.html.

ILMN has been the subject of several other research reports. Deutsche Bank AG set a $175.00 price target on Illumina and gave the company a “hold” rating in a report on Friday, July 28th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $215.00 in a report on Monday, August 7th. Morgan Stanley restated an “underweight” rating and set a $122.00 price target (up previously from $115.00) on shares of Illumina in a report on Monday, July 10th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target for the company. in a report on Wednesday, June 21st. Finally, Barclays PLC restated a “hold” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Illumina has a consensus rating of “Hold” and an average target price of $187.85.

Illumina (NASDAQ:ILMN) traded up 0.90% during mid-day trading on Thursday, reaching $208.54. The company had a trading volume of 514,959 shares. The firm has a 50-day moving average of $203.70 and a 200 day moving average of $185.30. Illumina has a 1-year low of $119.37 and a 1-year high of $214.34. The company has a market capitalization of $30.45 billion, a PE ratio of 41.84 and a beta of 0.76.

In related news, EVP Omead Ostadan sold 1,671 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $195.26, for a total transaction of $326,279.46. Following the completion of the sale, the executive vice president now directly owns 24,571 shares of the company’s stock, valued at approximately $4,797,733.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $197.00, for a total value of $316,973.00. Following the sale, the senior vice president now directly owns 9,037 shares of the company’s stock, valued at $1,780,289. The disclosure for this sale can be found here. Insiders have sold a total of 178,516 shares of company stock valued at $34,995,591 over the last three months. 1.60% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Advisory Services Network LLC increased its holdings in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the period. Penserra Capital Management LLC increased its holdings in Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the period. Paradigm Asset Management Co. LLC increased its holdings in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the period. Patten Group Inc. increased its holdings in Illumina by 2.7% during the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its holdings in Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the period. Institutional investors own 93.32% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.